Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors.

ABSTRACT:

Purpose

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has the potential to emerge as a distinct subtype. Several studies have compared the differences between HER2-low and HER2-0 breast cancers, but no consensus has been reached. Additionally, a biomarker to predict pathological complete response (pCR) rates in patients with HER2-low breast cancer remains to be identified.

Methods

We collected data from 777 patients across three centers, stratifying them into HER2-low and HER2-0 groups. We compared differences in survival and pCR rates between the two groups and investigated potential biomarkers that could reliably predict pCR.

Results

The study found that patients with HER2-0 breast cancer had higher pCR rates compared to patients with HER2-low tu

SUBMITTER: Zhang X 

PROVIDER: S-EPMC11885850 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature